Sugammadex
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anesthesia, General
Conditions
Anesthesia, General
Trial Timeline
Dec 5, 2005 → Oct 19, 2006
NCT ID
NCT00591786About Sugammadex
Sugammadex is a phase 2 stage product being developed by Merck for Anesthesia, General. The current trial status is completed. This product is registered under clinical trial identifier NCT00591786. Target conditions include Anesthesia, General.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05276804 | Phase 3 | Completed |
| NCT03196167 | Approved | Completed |
| NCT02011490 | Phase 1 | Completed |
| NCT00826176 | Phase 3 | Completed |
| NCT00702715 | Phase 3 | Completed |
| NCT00535496 | Phase 3 | Completed |
| NCT00591786 | Phase 2 | Completed |
| NCT00552929 | Phase 2 | Completed |
| NCT00482599 | Phase 3 | Completed |
Competing Products
20 competing products in Anesthesia, General